Effect of Nebulized Budesonide on Preventing Postextubation Complications in Critically Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is evaluation of the effect of administration nebulized budesonide
after extubation. The specific objectives of our study are to determine whether multiple
doses of nebulized budesonide are effective to reduce or prevent postextubation edema.
In this double-blind randomized clinical trial study, 70 patients (age between 18 to 65) who
are intubated (at least for 48 hours) and now are ready for extubation will be enrolled in
the study after obtaining a written informed consent from their parents or guardians.
The investigators divide our patients randomly into two equal groups.
-Patients who are in budesonide group will receive nebulized budesonide (1 mg-every 12 hours;
n=35) and patients in placebo group receive placebo (normal saline; n=35) until 48 hours
after extubation. If patient have extubation criteria the investigators will extubate him and
for 24 hours after, another anesthesiologist who is unaware about kind of medication, will
evaluate the patients for severity of stridor. We will record the vital sings and grade of
stridor every 6 hour. Respiratory rate (RR), heart rate (HR), blood pressure (BP) and oxygen
saturation (SPO2) were recorded for each patient immediately before aerosol administration
(time 0) and at 30 and 60 min; and 2,4,8,12,24,36 and 48 hrs. After extubation then the
presence of stridor (heard with the aid of stethoscope) was recorded within 48 hr of
extubation.